Development of a Diagnostic Programmed Cell Death 1-Ligand 1 Immunohistochemistry Assay for Nivolumab Therapy in Melanoma

Nivolumab is a monoclonal antibody that blocks the interaction between programmed cell death 1 (PD1) and programmed cell death 1-ligand 1 (PD-L1), resulting in enhanced antitumor activity by the immune system. Nivolumab is currently approved by the US Food and Drug Administration (FDA) for melanoma,...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Appl Immunohistochem Mol Morphol
Main Authors: Phillips, Therese, Millett, Molly M., Zhang, Xiaoling, Jansson, Malinka, Cleveland, Rachel, Simmons, Pauline, Cherryholmes, Gregory, Carnahan, Josette, William, Josette, Spaulding, Betsy, Satnick, Ilana R., Inzunza, H. David, Taylor, Clive, Cogswell, John, Novotny, James, Oroudjev, Emin, Winther, Henrik
Formato: Artigo
Idioma:Inglês
Publicado: Lippincott Williams & Wilkins 2018
Assuntos:
Reserch Articles
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5753812/
https://ncbi.nlm.nih.gov/pubmed/29189265
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/PAI.0000000000000605
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares